Cargando…
Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts
Several molecular biomarkers have been identified to guide induction treatment selection for localized pancreatic ductal adenocarcinoma (PDAC). SMAD4 alterations and low GATA6 expression/modified “Moffitt” basal-like phenotype have each been associated with inferior survival uniquely for patients re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669842/ https://www.ncbi.nlm.nih.gov/pubmed/38002058 http://dx.doi.org/10.3390/biomedicines11113058 |
_version_ | 1785149256963719168 |
---|---|
author | Greendyk, Joshua D. Allen, William E. Alexander, H. Richard Beninato, Toni Eskander, Mariam F. Grandhi, Miral S. Kennedy, Timothy J. Langan, Russell C. Maggi, Jason C. De, Subhajyoti Court, Colin M. Ecker, Brett L. |
author_facet | Greendyk, Joshua D. Allen, William E. Alexander, H. Richard Beninato, Toni Eskander, Mariam F. Grandhi, Miral S. Kennedy, Timothy J. Langan, Russell C. Maggi, Jason C. De, Subhajyoti Court, Colin M. Ecker, Brett L. |
author_sort | Greendyk, Joshua D. |
collection | PubMed |
description | Several molecular biomarkers have been identified to guide induction treatment selection for localized pancreatic ductal adenocarcinoma (PDAC). SMAD4 alterations and low GATA6 expression/modified “Moffitt” basal-like phenotype have each been associated with inferior survival uniquely for patients receiving 5-FU-based therapies. SMAD4 may directly regulate the expression of GATA6 in PDAC, pointing to a common predictive biomarker. To evaluate the relationship between SMAD4 mutations and GATA6 expression in human PDAC tumors, patients with paired SMAD4 mutation and GATA6 mRNA expression data in the TCGA and CPTAC were identified. In 321 patients (TCGA: n = 180; CPTAC: n = 141), the rate of SMAD4 alterations was 26.8%. The rate of SMAD4 alteration did not vary per tertile of normalized GATA6 expression (TCGA: p = 0.928; CPTAC: p = 0.828). In the TCGA, SMAD4 alterations and the basal-like phenotype were each associated with worse survival (log rank p = 0.077 and p = 0.080, respectively), but their combined presence did not identify a subset with uniquely inferior survival (p = 0.943). In the CPTAC, the basal-like phenotype was associated with significantly worse survival (p < 0.001), but the prognostic value was not influenced by the combined presence of SMAD4 alterations (p = 0.960). SMAD4 alterations were not associated with poor clinico-pathological features such as poor tumor grade, advanced tumor stage, positive lymphovascular invasion (LVI), or positive perineural invasion (PNI), compared with SMAD4-wildtype. Given that SMAD4 mutations were not associated with GATA6 expression or Moffitt subtype in two independent molecularly characterized PDAC cohorts, distinct biomarker-defined clinical trials are necessary. |
format | Online Article Text |
id | pubmed-10669842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106698422023-11-15 Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts Greendyk, Joshua D. Allen, William E. Alexander, H. Richard Beninato, Toni Eskander, Mariam F. Grandhi, Miral S. Kennedy, Timothy J. Langan, Russell C. Maggi, Jason C. De, Subhajyoti Court, Colin M. Ecker, Brett L. Biomedicines Article Several molecular biomarkers have been identified to guide induction treatment selection for localized pancreatic ductal adenocarcinoma (PDAC). SMAD4 alterations and low GATA6 expression/modified “Moffitt” basal-like phenotype have each been associated with inferior survival uniquely for patients receiving 5-FU-based therapies. SMAD4 may directly regulate the expression of GATA6 in PDAC, pointing to a common predictive biomarker. To evaluate the relationship between SMAD4 mutations and GATA6 expression in human PDAC tumors, patients with paired SMAD4 mutation and GATA6 mRNA expression data in the TCGA and CPTAC were identified. In 321 patients (TCGA: n = 180; CPTAC: n = 141), the rate of SMAD4 alterations was 26.8%. The rate of SMAD4 alteration did not vary per tertile of normalized GATA6 expression (TCGA: p = 0.928; CPTAC: p = 0.828). In the TCGA, SMAD4 alterations and the basal-like phenotype were each associated with worse survival (log rank p = 0.077 and p = 0.080, respectively), but their combined presence did not identify a subset with uniquely inferior survival (p = 0.943). In the CPTAC, the basal-like phenotype was associated with significantly worse survival (p < 0.001), but the prognostic value was not influenced by the combined presence of SMAD4 alterations (p = 0.960). SMAD4 alterations were not associated with poor clinico-pathological features such as poor tumor grade, advanced tumor stage, positive lymphovascular invasion (LVI), or positive perineural invasion (PNI), compared with SMAD4-wildtype. Given that SMAD4 mutations were not associated with GATA6 expression or Moffitt subtype in two independent molecularly characterized PDAC cohorts, distinct biomarker-defined clinical trials are necessary. MDPI 2023-11-15 /pmc/articles/PMC10669842/ /pubmed/38002058 http://dx.doi.org/10.3390/biomedicines11113058 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Greendyk, Joshua D. Allen, William E. Alexander, H. Richard Beninato, Toni Eskander, Mariam F. Grandhi, Miral S. Kennedy, Timothy J. Langan, Russell C. Maggi, Jason C. De, Subhajyoti Court, Colin M. Ecker, Brett L. Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title_full | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title_fullStr | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title_full_unstemmed | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title_short | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts |
title_sort | association between smad4 mutations and gata6 expression in paired pancreatic ductal adenocarcinoma tumor specimens: data from two independent molecularly-characterized cohorts |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669842/ https://www.ncbi.nlm.nih.gov/pubmed/38002058 http://dx.doi.org/10.3390/biomedicines11113058 |
work_keys_str_mv | AT greendykjoshuad associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT allenwilliame associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT alexanderhrichard associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT beninatotoni associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT eskandermariamf associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT grandhimirals associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT kennedytimothyj associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT langanrussellc associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT maggijasonc associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT desubhajyoti associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT courtcolinm associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts AT eckerbrettl associationbetweensmad4mutationsandgata6expressioninpairedpancreaticductaladenocarcinomatumorspecimensdatafromtwoindependentmolecularlycharacterizedcohorts |